PRLD — Prelude Therapeutics Inc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1678660 ·
Last close
$3.32
Market Cap
$216.05M
52W High
$6.83
52W Low
$1.29
ADV30
376,310
Next earnings
2026-11-16
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 5,647,000 | — | -14,265,000 | -12,544,000 | 175,485,000 | 23,412,000 | 51,349,000 |
| Jun 2026 | 5,704,000 | — | -15,454,000 | -13,921,000 | 189,363,000 | 26,329,000 | 55,630,000 |
| Mar 2026 | 4,580,000 | — | -14,177,000 | -10,385,000 | 119,642,000 | 21,756,000 | 59,459,000 |
| Dec 2025 | 5,640,000 | — | -17,348,000 | -16,457,000 | 141,315,000 | 35,256,000 | 72,678,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-33,255,000
Investing CF
$-77,252,000
Financing CF
$110,445,000
CapEx
$-67,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.94
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-707,367,000
Inventory
—
Receivables
—
ST Investments
$125,428,000
EBIT TTM
$-67,397,000
Pretax Income TTM
$-60,488,000
Interest Exp TTM
—
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$22,424,000
EBITDA
$-64,510,000
Free Cash Flow
$-13,844,625
Enterprise Value
$338,639,712
Total Cash
$151,756,992
Total Debt
$17,650,000
Shares Out
65,075,350
Trailing EPS
$-0.73
Book Value
$1.30
ROE
-57.7%
ROA
-27.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 12,140,000 | -104,566,000 | -99,498,000 | 141,315,000 | 72,678,000 | 68,637,000 | -56,302,000 |
| Dec 2024 | 7,000,000 | -139,714,000 | -127,173,000 | 175,515,000 | 44,056,000 | 131,459,000 | -102,888,000 |
| Dec 2023 | 0 | -132,277,000 | -121,832,000 | 277,665,000 | 40,575,000 | 237,090,000 | -107,063,000 |
| Dec 2022 | 0 | -123,540,000 | -115,438,000 | 220,500,000 | 25,063,000 | 195,437,000 | -83,729,000 |
TTM Snapshot
Revenues TTM
$22,424,000
NetIncome TTM
$-60,488,000
OpCashFlow TTM
—
Assets (Latest)
$189,363,000
Forward EPS
$-0.75
Max Pain — expiry 2027-03-19 (volume-derived — Yahoo OI feed degraded)
max pain strike: $5.00 · spot: $3.30 · call volume: 24 · put volume: 30Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LAB | STANDARD BIOTOOLS INC. | $212.95M | $0.54 | — |
| NGEN | NERVGEN PHARMA CORP. | $210.74M | $1.96 | — |
| KROS | Keros Therapeutics, Inc. | $221.95M | $11.31 | — |
| ACIU | AC Immune SA | $209.79M | $2.11 | — |
| IMRX | Immuneering Corp | $224.08M | $3.46 | — |
News headlines (Yahoo Finance, 1h cache)
Prelude Therapeutics Incorporated (PRLD) Reports Q3 Loss, Beats Revenue Estimates
2026-11-16 12:15 · Yahoo
Prelude Therapeutics Incorporated (PRLD) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
2026-11-04 14:00 · Yahoo
Prelude Therapeutics Spotlights JAK2, KAT6A Programs and Potential $100M Incyte Option
2026-10-23 03:02 · Yahoo
Prelude Therapeutics to Participate in the Chardan Healthcare Conference
2026-10-16 20:01 · Yahoo
Down 27.4% in 4 Weeks, Here's Why Prelude Therapeutics (PRLD) Looks Ripe for a Turnaround
2026-10-16 12:35 · Yahoo
Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Brea
2026-10-13 11:01 · Yahoo
Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-11 11:01 · Yahoo
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader
2026-09-10 11:01 · Yahoo
Prelude Therapeutics (PRLD) Upgraded to Buy: Here's Why
2026-07-17 16:00 · Yahoo
Goldman Sachs Initiates Coverage of Prelude Therapeutics (PRLD)
2026-05-31 10:55 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.